Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y educación

21 Octubre, 2024

Enviado por remote_content el Lun, 21/10/2024 - 08:43

Enfermedades infecciosas

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

Knowledge, attitudes, and behavior regarding antibiotics, antibiotic use, and antibiotic resistance in students and health care professionals of the district of Barranquilla (Colombia): A cross-sectional survey. Heliyon.

Noviembre 1, 2022

Enfermedades infecciosas

Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata. J Antimicrob Chemother.

Febrero 23, 2022

Enfermedades infecciosas

Falla D. Citoquinas pro y antiinflamatorias en la infección por SARS-CoV-2, en población de Colombia. Infectio

Noviembre 9, 2020